Epizyme, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2007-01-01
- Employees
- 250
- Market Cap
- -
- Website
- http://www.epizyme.com
Clinical Trials
50
Trial Phases
3 Phases
Drug Approvals
2
Drug Approvals
Tazemetostat Hydrobromide Tablets
- Product Name
- 达唯珂
- Approval Number
- 国药准字HJ20250031
- Approval Date
- Mar 18, 2025
Clinical Trials
Distribution across different clinical trial phases (46 trials with phase data)• Click on a phase to view related trials
A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation
- Conditions
- Follicular LymphomaRefractory Follicular Lymphoma
- Interventions
- First Posted Date
- 2023-10-05
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Epizyme, Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT06068881
A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.
- Conditions
- Relapsed Hematologic MalignancyRefractory Hematologic Malignancy
- Interventions
- First Posted Date
- 2022-01-25
- Last Posted Date
- 2023-08-15
- Lead Sponsor
- Epizyme, Inc.
- Registration Number
- NCT05205252
- Locations
- 🇺🇸
California Cancer Associates For Research And Excellence, cCARE, Santa Fe, California, United States
🇺🇸Central Care Cancer Center, Bolivar, Missouri, United States
🇺🇸Astera Cancer Center, East Brunswick, New Jersey, United States
A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
- Conditions
- Diffuse Large B Cell Lymphoma RefractoryDiffuse Large B-Cell LymphomaMultiple Myeloma, RefractoryMultiple Myeloma in Relapse
- Interventions
- First Posted Date
- 2021-11-16
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Epizyme, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT05121103
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Astera Cancer Care, East Brunswick, New Jersey, United States
🇺🇸Weill Cornell Medicine, New York, New York, United States
SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
- Conditions
- Follicular Lymphoma
- Interventions
- Combination Product: Rituximab
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- Epizyme, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT04762160
- Locations
- 🇺🇸
Alabama Oncology, Birmingham, Alabama, United States
🇺🇸Compassionate Cancer Care, Fountain Valley, California, United States
🇺🇸USOR/Rocky Mountain Cancer Centers, Boulder, Colorado, United States
Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels
- Conditions
- Epithelioid Sarcoma (ES)Hematologic MalignancyDiffuse Large B-Cell Lymphoma (DLBCL)Rhabdoid TumorAll MalignanciesFollicular Lymphoma (FL)Non-Hodgkin Lymphoma (NHL)Renal Medullary CarcinomaMesotheliomaAdvanced Malignancies
- Interventions
- First Posted Date
- 2020-09-03
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- Epizyme, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT04537715
- Locations
- 🇺🇸
California Cancer Associates for Research and Excellence, Inc. (cCARE), Encinitas, California, United States
🇺🇸The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸Northwestern University-Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
China's NMPA Grants Conditional Approval to Tazemetostat for EZH2-Mutant Follicular Lymphoma
China's National Medical Products Administration (NMPA) has granted conditional approval to tazemetostat (Tazverik) for adult patients with relapsed or refractory EZH2-mutated follicular lymphoma who have received at least two prior systemic therapies.
China Grants Conditional Approval for Tazverik to Treat Relapsed or Refractory Follicular Lymphoma
China's National Medical Products Administration (NMPA) has conditionally approved Tazverik (tazemetostat) for adult patients with relapsed or refractory follicular lymphoma with EZH2 mutation who have received at least two prior systemic therapies.